THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.8]-CMP54 ID: TIP-MED-000324

Norfloxacin IP

Active Ingredient / Scientific Identity: Norfloxacin IP • Class: Second-Generation Fluoroquinolone Antibiotic (Bactericidal DNA Gyrase & Topoisomerase IV Inhibitor; WHO 'Watch' Group)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Norfloxacin IP ([8.8]-CMP54 | ID: TIP-MED-000324) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/8-8-cmp54-norfloxacin-ip/
Generic / Entity NameNorfloxacin IP ([8.8]-CMP54)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSecond-Generation Fluoroquinolone Antibiotic (Bactericidal DNA Gyrase & Topoisomerase IV I
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug • NLEM 2022 Core Essential Medicine
Key Warning & Review DateNo adjustment required unless combined with severe renal failure.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • NLEM 2022 Core Essent✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Norfloxacin IP (TIP-MED-000324, Reference Code [8.8]-CMP54) is classified under Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Second-Generation Fluoroquinolone Antibiotic (Bactericidal DNA Gyrase & Topoisomerase IV Inhibitor; WHO 'Watch' Group). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Essential Medicine.

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-8-21). Luminal/urinary fluoroquinolone (400 mg BD) for uncomplicated cystitis and cirrhotic SBP prophylaxis.
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-8-21). Luminal/urinary fluoroquinolone (400 mg BD) for uncomplicated cystitis and cirrhotic SBP prophylaxis.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-8-21). Luminal/urinary fluoroquinolone (400 mg BD) for uncomplicated cystitis and cirrhotic SBP prophylaxis.

4. Therapeutic Indications & Evidence-Supported Uses

  • Complicated urinary tract infections, acute pyelonephritis, and chronic bacterial prostatitis
  • Infectious bacterial gastroenteritis (shigellosis, cholera, invasive salmonellosis where susceptible) and Pseudomonas aeruginosa infections
  • Anthrax post-exposure prophylaxis and meningococcal chemoprophylaxis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-8-21). Luminal/urinary fluoroquinolone (400 mg BD) for uncomplicated cystitis and cirrhotic SBP prophylaxis.

Administration & Meal Timing: Oral (with water, away from dairy/antacids) or IV infusion over 60 minutes.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [8.8].
Metabolism & Biotransformation:
No adjustment required unless combined with severe renal failure.
Elimination & Renal Adjustment:
Reduce dose by 50% or extend interval to q18–24h when CrCl < 30 mL/min.
Hepatic Impairment Considerations:
No adjustment required unless combined with severe renal failure.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Myasthenia gravis (blocks neuromuscular transmission and can precipitate fatal respiratory muscle weakness)
  • History of fluoroquinolone-associated tendinitis or tendon rupture
  • Concomitant Tizanidine (Ciprofloxacin inhibits CYP1A2 and increases Tizanidine AUC by 10-fold, causing profound hypotension and sedation!)

Key Clinical Precautions: No adjustment required unless combined with severe renal failure.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Tendinitis and spontaneous Achilles tendon rupture (mediated by matrix metalloproteinase upregulation and collagen degradation — highest risk in >60 yr, renal failure, or corticosteroid use)
  • Peripheral neuropathy, CNS excitation (insomnia, dizziness, lowered seizure threshold via GABA-A antagonism, especially if combined with NSAIDs)
  • QTc prolongation and aortic aneurysm/dissection risk in high-risk vascular patients
Serious / Dose-Limiting Adverse Effects:
  • Arthropathy in weight-bearing cartilage of immature animals

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Antacids (Al/Mg), Calcium, Iron, Zinc, Sucralfate, & Dairy products (milk/curd): chelate the 3-carboxyl-4-keto group of Ciprofloxacin and reduce bioavailability by up to 90% — take Ciprofloxacin 2 hours before or 6 hours after cations
  • Theophylline, Tizanidine, Clozapine, Duloxetine, Caffeine, & R-Warfarin: Ciprofloxacin potently inhibits CYP1A2, precipitating Theophylline seizures/arrhythmias and Tizanidine collapse
  • Corticosteroids: markedly increases risk of Achilles tendonitis and tendon rupture (especially in patients aged >60 yr)
  • QT-prolonging drugs & Sulfonylureas: additive QTc prolongation and dysglycaemia

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [8.8].

Pharmacist Patient Counselling Points:

  • Do NOT take Ciprofloxacin with milk, curd/yogurt, calcium tablets, iron supplements, or antacids — take with plain water at least 2 hours before or 6 hours after any mineral or dairy product.
  • Stop taking immediately and rest the limb if pain, swelling, or inflammation develops in the Achilles tendon or ankle.
  • Do not use empirically for suspected Tuberculosis (delays TB diagnosis and breeds fluoroquinolone-resistant MDR-TB).

Storage, Stability & Dispensing Safeguards: Store below 30°C protected from light.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/8-8-cmp54-norfloxacin-ip/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.